Table of Contents
Thrombosis
Volume 2012 (2012), Article ID 108983, 10 pages
http://dx.doi.org/10.1155/2012/108983
Review Article

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

1Department of Cardiology, National Heart Centre Singapore, 17 Third Hospital Avenue, Singapore 168752
2Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857
3Department of Cardiology, National University Heart Centre, 5 Lower Kent Ridge Road, Singapore 119074
4Mount Elizabeth Medical Centre, 3 Mount Elizabeth No. 14-10, Singapore 228510
5Mount Elizabeth Medical Centre, 3 Mount Elizabeth No. 14-01, Singapore 228510
6Gleneagles Medical Centre, 6 Napier Road No. 03-04, 25499, Singapore
7Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433

Received 29 June 2012; Accepted 1 August 2012

Academic Editor: Walter Ageno

Copyright © 2012 Tan Ru San et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Tan Ru San, Mark Yan Yee Chan, Teo Wee Siong, et al., “Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban,” Thrombosis, vol. 2012, Article ID 108983, 10 pages, 2012. doi:10.1155/2012/108983